home edit2 whole TSD November 2002 PDF format - OEHHA

eceiving TPA was 0/35, 4/34, 4/32 and 13/32 (number of animals with tumors/number of animals
examined) for the control, low, mid and high dose groups, respectively; the skin tumor incidence in
animals receiving 300 mg/kg acrylamide but not TPA was 10/36. Acrylamide-treated animals also
demonstrated a significant dose-related increase in the incidence of lung tumors (alveolar and
bronchiolar adenomas and carcinomas). The incidence in animals also receiving TPA was 4/36, 8/34,
6/36 and 11/34 for the control, low, mid and high dose groups, respectively; the lung tumor incidence in
animals receiving 300 mg/kg acrylamide but not TPA was 14/36.
Table 1.
Skin tumor (squamous cell papillomas and carcinomas) incidence in female Sencar mice
exposed to acrylamide (Bull et al., 1984a)
Total administered
dose 1
(mg/kg body weight)
Route of administration TPA 2 Tumor incidence
0 gavage + 2/40
75 + 12/40
100 + 23/40
300 + 30/40
300 - 0/20
0 intraperitoneal injection + 0/40
75 + 10/40
100 + 13/40
300 + 21/40
300 - 0/20
0 dermal + 7/40
75 + 4/40
100 + 11/40
300 + 18/40
300 - 0/20
1. The exposure duration was less than lifetime (2 weeks); the total administered dose listed was
not adjusted to reflect a less-than-lifetime exposure.
2. TPA = 12-O-tetradecanoyl-phenol-13-acetate
33